摘要
目的:探讨依折麦布联合辛伐他汀对冠心病患者血脂及炎性因子的调节作用。方法:选取2011年5月～9月我院收治的冠心病患者60例,随机分为试药组和对照组,每组各30例,试药组采用依折麦布(10 mg/d)联合辛伐他汀(20 mg/d),对照组单独使用辛伐他汀(40 mg/d)。在服药前、用药4周、用药8周时分别测定总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)、肝功能、肾功能、肌酸激酶(CK)。结果:与用药前基线水平相比,两组用药4周TC、LDL-C水平均显著下降(P<0.05),治疗8周均进一步下降(P<0.01),并且与对照组相比,试药组8周TC、LDL-C下降水平更显著(P<0.05)。两组患者的肝功能、肾功能、CK在用药后均无明显异常。结论:依折麦布联合辛伐他汀能更有效地降低冠心病患者血脂水平。
To explore the regulatory effect of ezetimibe combined with simvastatin on lipid and inflammatory cytokines in patients with coronary heart disease （CHD）. METHODS： Sixty patients with CHD admitted to our hospital between May 2011 and September 2011 were randomly divided into two groups： treatment group and control group （30 patients/group）. Ezetimibe （10 mg/day） combined with simvastatin （20 mg/day） was used in the treatment group and independent simvastatin （40 mg/day） was administered in the control group. Total cholesterol （TC）, triglyceride （TG）, low-density lipoprotein cholesterol （LDL-C）, high-density lipoprotein cholesterol （HDL-C）, hepatic function, renal function, and creatine kinase （CK） were examined, respectively, before administration and 4 weeks and 8 weeks after administration. RESULTS： Compared with baseline level, TC and LDL-C decreased in the two groups 4 weeks after administration （ P 〈 0.05 ）. After 8 weeks, these indicators decreased further in both groups （P 〈 0.01 ）. Compared with those in control group, TC and LDL-C in treatment group signif- icantly decreased after 8 weeks （ P 〈 0.05 ）. No significant differences of hepatic function, renal function and CK were found in both groups. CONCLUSION： Ezetimibe combined with simvastatin was shown to be more effective in decreasing serum lipid concentrations in patients with CHD.
出处
《心脏杂志》
CAS
2012年第3期388-390,共3页
Chinese Heart Journal
